Over four decades of commercial wisdom
Both Kevin and Beatriz combine to drive operational speed, scientific excellence and collaboration.
Dr Kevin Moulder
He brings over 30 years of experience in drug discovery and development in the fields of protein design, antibody technology, immuno-oncology, inflammation and autoimmune disease.
Following his post-doctoral studies at the NIH, he joined GSK to lead their CD23 program. Thereafter, he served in research and development leadership positions in 9 international biotechnology companies including Biogen where he ran a predictive medicine department. As VP of Research at Domantis, Kevin led the creation of a pipeline of novel single domain antibodies resulting in Domantis’ acquisition by GSK.
Subsequently, Dr. Moulder served as the CSO of F-Star Therapeutics, where he established the company’s bispecific antibody technology and led the translational efforts to identify its first clinical lead.
Most recently Kevin held C-level positions at Medicenna Therapeutics, PolyProx Therapeutics Ltd. and Tusk Therapeutics. At Tusk, Kevin directed the development of their anti-CD25 antibody which showed anticancer activity by depleting Tregs while preserving IL-2 activity on effector T cells, which subsequently prompted Tusk’s acquisition by Roche.
Kevin holds a first class honors degree in biological sciences and a Ph.D in Immunology from the University of London.
Dr Kevin Moulder creates high-performance biotech companies which benefit both investors and patients.
Dr. Beatriz Goyenechea
She is an expert in the early-stage biotech sector, heading both Research Operations and R&D activities in the antibody and target discovery fields.
Dr. Goyenechea has over a decade of experience in drug discovery and development in the fields of protein/antibody engineering, immuno-oncology, oncology and target identification and validation.
Beatriz holds a first-class honours degree in Biochemistry and did her PhD in Molecular Immunology in Cesar Milstein’s lab at the LMB. She then did postdoctoral studies creating and studying mouse models carrying the human SDS gene, IgG and B globin loci at the Babraham Institute and the LMB/Cambridge University.
She joined F-star to start up their operations and discovery activities in the UK. Thereafter, she served in R&D and operational leadership roles in several biotechnology companies including Biosceptre, Avacta, Black Belt Therapeutics, Tusk Therapeutics, PolyProx Therapeutics and Medicenna Therapeutics.
At Tusk, Beatriz directed the discovery of their anti-CD25 antibody which showed anticancer activity by depleting Tregs while preserving IL-2 activity on effector T cells, which led to Tusk’s acquisition by Roche.
Dr. Beatriz Goyenechea is passionate about the creation of and materialisation of ideas with scientific integrity. Which ultimately benefits both investors and patients.
